Department of Medical Services and Clinical Research, NeuroGen Brain & Spine Institute, Navi Mumbai, Maharashtra, India.
Eur Rev Med Pharmacol Sci. 2021 May;25(9):3632-3639. doi: 10.26355/eurrev_202105_25847.
In the current pandemic, Health Care Workers (HCWs) are at a high risk of developing COVID-19. Preventive methods like the use of personal protective equipment, isolation, social distancing, and chemoprophylaxis show limited benefit. Despite standard prophylaxis, many of the HCWs develop COVID-19. Medical ozone therapy has immunomodulatory, antioxidant and antiviral effect, and, therefore, it can be explored as prophylaxis for COVID-19.
We conducted a retrospective controlled cohort study. IV ozonized saline was administered once a day for a total of 4 days in one month in addition to standard prophylaxis for COVID-19 to HCWs in a dedicated COVID hospital. Fresh ozonized saline was prepared for every administration and was given over 1 hour.
There were 235 HCWs, 64 received the ozone prophylaxis and 171 did not. The incidence of COVID-19 was significantly (p=0.04) lesser in HCWs that received ozone prophylaxis (4.6%) as compared to those who did not (14.03%). The benefit was seen irrespective of the risk of exposure. In the red zone, 8.69% of the HCWs who received ozone prophylaxis tested positive as opposed to 15.3% of those who did not. In the orange zone, 4.34% of the HCWs who received ozone prophylaxis tested positive, remarkably lesser than those who did not (20%). In the green zone, none of the HCWs who received ozone prophylaxis tested positive; however, 3.4% of the HCWs who did not receive ozone prophylaxis tested positive. No major adverse events were noted.
IV ozonized saline can be used in addition to the standard prophylactic regimen for the prevention of COVID-19 in HCWs. Prospective larger studies are required to establish the potency of IV ozonized saline as prophylaxis.
在当前的大流行中,医护人员(HCWs)感染 COVID-19 的风险很高。使用个人防护设备、隔离、社交距离和化学预防等预防方法的效果有限。尽管进行了标准预防,但仍有许多 HCWs 感染 COVID-19。医用臭氧疗法具有免疫调节、抗氧化和抗病毒作用,因此可以探索其作为 COVID-19 的预防方法。
我们进行了一项回顾性对照队列研究。在专门的 COVID 医院中,除了 COVID-19 的标准预防外,HCWs 每月接受一次为期 4 天的每日静脉注射臭氧生理盐水治疗。每次给药时都会准备新鲜的臭氧生理盐水,并在 1 小时内给药。
共有 235 名 HCWs,其中 64 名接受了臭氧预防治疗,171 名未接受。接受臭氧预防治疗的 HCWs 的 COVID-19 发病率明显(p=0.04)较低(4.6%),而未接受的 HCWs 发病率为 14.03%。这种益处与暴露风险无关。在红色区域,接受臭氧预防治疗的 HCWs 中有 8.69%的检测结果呈阳性,而未接受臭氧预防治疗的 HCWs 中有 15.3%的检测结果呈阳性。在橙色区域,接受臭氧预防治疗的 HCWs 中有 4.34%的检测结果呈阳性,明显低于未接受臭氧预防治疗的 HCWs(20%)。在绿色区域,接受臭氧预防治疗的 HCWs 中没有人检测结果呈阳性;然而,有 3.4%的未接受臭氧预防治疗的 HCWs 检测结果呈阳性。未发现重大不良事件。
除了标准预防方案外,静脉注射臭氧生理盐水可用于预防 HCWs 的 COVID-19。需要进行更大规模的前瞻性研究,以确定静脉注射臭氧生理盐水作为预防措施的效力。